498 related articles for article (PubMed ID: 29636755)
21. Preclinical development of BCG.HIVA
Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
[TBL] [Abstract][Full Text] [Related]
22. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.
Gu R; Shampang A; Nashar T; Patil M; Fuller DH; Ramsingh AI
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824074
[TBL] [Abstract][Full Text] [Related]
23. Immune responses against a new HIV-1 p24-gp41/pCAGGS-IL-12 DNA vaccine in Balb/c mice.
Roodbari F; Sabahi F; Sarbolouki MN; Barkhordari F; Adeli A; Jamedar A; Mahboudi F
Iran J Immunol; 2012 Jun; 9(2):86-97. PubMed ID: 22735796
[TBL] [Abstract][Full Text] [Related]
24. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
25. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.
Honda M; Matsuo K; Nakasone T; Okamoto Y; Yoshizaki H; Kitamura K; Sugiura W; Watanabe K; Fukushima Y; Haga S; Katsura Y; Tasaka H; Komuro K; Yamada T; Asano T; Yamazaki A; Yamazaki S
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10693-7. PubMed ID: 7479867
[TBL] [Abstract][Full Text] [Related]
26. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
[TBL] [Abstract][Full Text] [Related]
27. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
28. Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice.
Lagranderie M; Balazuc AM; Gicquel B; Gheorghiu M
J Virol; 1997 Mar; 71(3):2303-9. PubMed ID: 9032366
[TBL] [Abstract][Full Text] [Related]
29. The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen.
Chapman R; Bourn WR; Shephard E; Stutz H; Douglass N; Mgwebi T; Meyers A; Chin'ombe N; Williamson AL
PLoS One; 2014; 9(7):e103314. PubMed ID: 25061753
[TBL] [Abstract][Full Text] [Related]
30. Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.
Ranganathan UD; Larsen MH; Kim J; Porcelli SA; Jacobs WR; Fennelly GJ
Vaccine; 2009 Dec; 28(1):152-61. PubMed ID: 19808028
[TBL] [Abstract][Full Text] [Related]
31. The development of a novel Mycobacterium-Escherichia coli shuttle vector system using pMyong2, a linear plasmid from Mycobacterium yongonense DSM 45126T.
Lee H; Kim BJ; Kim BR; Kook YH; Kim BJ
PLoS One; 2015; 10(3):e0122897. PubMed ID: 25822634
[TBL] [Abstract][Full Text] [Related]
32. Protective immunity of recombinant Mycobacterium bovis BCG expressing rhomboid gene against Eimeria tenella challenge.
Wang Q; Li J; Zhang X; Liu Q; Liu C; Ma G; Cao L; Gong P; Cai Y; Zhang G
Vet Parasitol; 2009 Mar; 160(3-4):198-203. PubMed ID: 19117681
[TBL] [Abstract][Full Text] [Related]
33. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.
Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Sutthent R; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):113-22. PubMed ID: 19323043
[TBL] [Abstract][Full Text] [Related]
35. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
36. Role for Gr-1+ cells in the control of high-dose Mycobacterium bovis recombinant BCG.
Panas MW; Letvin NL
Clin Vaccine Immunol; 2014 Aug; 21(8):1120-7. PubMed ID: 24920602
[TBL] [Abstract][Full Text] [Related]
37. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.
Cayabyab MJ; Korioth-Schmitz B; Sun Y; Carville A; Balachandran H; Miura A; Carlson KR; Buzby AP; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2009 Jun; 83(11):5505-13. PubMed ID: 19297477
[TBL] [Abstract][Full Text] [Related]
38. Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.
Climent N; Munier S; Piqué N; García F; Pavot V; Primard C; Casanova V; Gatell JM; Verrier B; Gallart T
Vaccine; 2014 Oct; 32(47):6266-76. PubMed ID: 25240755
[TBL] [Abstract][Full Text] [Related]
39. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.
Rosario M; Hopkins R; Fulkerson J; Borthwick N; Quigley MF; Joseph J; Douek DC; Greenaway HY; Venturi V; Gostick E; Price DA; Both GW; Sadoff JC; Hanke T
J Virol; 2010 Jun; 84(12):5898-908. PubMed ID: 20375158
[TBL] [Abstract][Full Text] [Related]
40. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
